(Betamethasone acetate + betamethasone sodium phosphate) is a Small Molecule owned by Merck & Co, and is involved in 1 clinical trial, which is ongoing.
Betamethasone is a glucocorticoid receptor agonist. It mainly induces the phospholipase A2 inhibitory proteins and inhibits the common precursor called arachidonic acid. At cellular level, it induces peptides called lipocortins. Lipocortins antagonize phospholipase A2, an enzyme which causes the breakdown of leukocyte lysosomal membranes to release arachidonic acid. This leads to a decrease in the amount of potent mediators like prostaglandins and leukotrienes, which are responsible for inflammations.
The revenue for (Betamethasone acetate + betamethasone sodium phosphate) is expected to reach a total of $2.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the (Betamethasone acetate + betamethasone sodium phosphate) NPV Report.
(Betamethasone acetate + betamethasone sodium phosphate) is currently owned by Merck & Co. Organon is the other company associated in development or marketing of (Betamethasone acetate + betamethasone sodium phosphate).
(Betamethasone acetate + betamethasone sodium phosphate) Overview
Betamethasone acetate and betamethasone sodium phosphate (Celestone Soluspan, Celestone Cronodose, Diprospan, Celestan, Betamethasone Acetate + Betamethasone Sodium Phosphate Exela) is a fixed dose combination acts as a corticosteroid and immunosuppressive agent. It is formulated as suspension for intrabursal , intramuscular , Intracavitary, intra-articular, intralesional, periarticular and intradermal administration. It is indicated for the Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions, Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome), endocrine disorders such as congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis, gastrointestinal Diseases over a critical period of the disease in regional enteritis and ulcerative colitis, hematologic disorders such as acquired (autoimmune) hemolytic anemia, diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block, leukemias and lymphomas, cerebral edema associated with primary or metastatic brain tumor or craniotomy, ophthalmic diseases such as sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids, renal diseases and respiratory diseases such as berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias and symptomatic sarcoidosis. It is also used as an adjunctive therapy for short-term administration in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis, for the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.
Organon is a healthcare company. The company discovers and develops biosimilars and medicines. It provides medicines and solutions for various conditions including respiratory, cardiovascular, dermatology, non-opioid pain, women’s health and others. The company’s products include mometasone furoate inhalation powder, follitropin beta injection, alendronate sodium, acetate injection, chorionic gonadotropin and others. It conducts patient assistance and Organon access program, which provide free medicines to individuals. Organon markets its products through a network of distribution channels in domestic and overseas markets. It works in collaboration with pharmaceutical and biopharmaceutical companies to commercialize its products. Organon is headquartered in Jersey City, New Jersey, the US.
The company reported revenues of (US Dollars) US$6,304 million for the fiscal year ended December 2021 (FY2021), a decrease of 3.5% over FY2020. In FY2021, the company’s operating margin was 24.3%, compared to an operating margin of 42.1% in FY2020. In FY2021, the company recorded a net margin of 21.4%, compared to a net margin of 33.1% in FY2020. The company reported revenues of US$1,537 million for the third quarter ended September 2022, a decrease of 3% over the previous quarter.
Quick View – (Betamethasone acetate + betamethasone sodium phosphate)
|Highest Development Stage|